1. Home
  2. |Insights
  3. |Satellite-Sensor FCA Suit Comes Crashing Down to Earth

Satellite-Sensor FCA Suit Comes Crashing Down to Earth

Client Alert | 1 min read | 08.09.17

On August 3, 2017 in United States ex rel. Mateski v. Raytheon Co, a district judge in the Central District of California dismissed a $1 billion False Claims Act (FCA) suit brought by a former Raytheon engineer who alleged that the company overbilled the government and failed to meet product specifications on a contract for satellite sensors. Although Relator had amended his complaint five times, the Fifth Amended Complaint still failed to identify a single specific false representation that Raytheon made to the government. Moreover, the complaint contained only one sentence addressing the materiality of Raytheon’s alleged nonconformity with contract specifications. Citing the Supreme Court’s decision in United States ex rel. Escobar on the implied certification theory of liability, the district court found that relator’s barebones allegations of nonconforming deliveries failed to meet the FCA’s demanding materiality standard and the heightened pleading requirements of 9(b) which were unlikely to be cured by granting further leave to amend.

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...